Drug Information

Drug General Information
Drug ID
D03BQP
Former ID
DNC001200
Drug Name
Rebamipide
Drug Type
Small molecular drug
Indication Peptic ulcer [ICD9: 531-534; ICD10:K25-K27] Phase 3 [525764], [543262]
Structure
Download
2D MOL

3D MOL
Formula
C19H15ClN2O4
InChI
InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)
InChIKey
ALLWOAVDORUJLA-UHFFFAOYSA-N
CAS Number
CAS 111911-87-6
PubChem Compound ID
5042
PubChem Substance ID
5392994, 7848184, 8153104, 11372977, 11483873, 11487855, 11491774, 12013207, 14877402, 26612890, 26680453, 26749027, 26749028, 29224113, 48328567, 50043069, 50043070, 53787206, 57322578, 74747436, 85175212, 85788525, 88277041, 91011744, 92124604, 92309229, 92713511, 99582548, 104308112, 117664455, 117772935, 118842287, 124637454, 124891853, 124971198, 125275481, 125307349, 125312449, 125325998, 125337900, 125810026, 126617864, 126624745, 126640517, 126663153, 126683520, 127423927, 131294612, 131329793, 131784276
Target and Pathway
Target(s) FMLP receptor Target Info Antagonist [535135]
KEGG Pathway Rap1 signaling pathway
Neuroactive ligand-receptor interaction
Staphylococcus aureus infection
NetPath Pathway Leptin Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Pathway Interaction Database Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
Reactome G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Human Complement System
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 525764The roles of prostaglandin E receptor subtypes in the cytoprotective action of prostaglandin E2 in rat stomach. Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:116-24.
Ref 543262(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 871).
Ref 535135Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther. 2001 Apr;297(1):388-94.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.